Monsenso AS (OCSE:MONSO) Other Stockholders Equity: kr0.06 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OCSE:MONSO Monsenso AS OCSE:MONSO
29 GF Score
Price kr0.30
GF Value kr0.15
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Monsenso AS Other Stockholders Equity?

Monsenso AS OCSE:MONSO -18.03% 29 Other Stockholders Equity is kr0.06 Mil as of Dec. 2025. GuruFocus rates OCSE:MONSO with a GF Score™ of 29/100 and a GF Value™ of kr0.15 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Monsenso AS's Other Stockholders Equity for the quarter that ended in Dec. 2025 was kr0.06 Mil.

Monsenso AS's quarterly Other Stockholders Equity declined from Dec. 2024 (kr0.06 Mil) to Jun. 2025 (kr0.06 Mil) but then increased from Jun. 2025 (kr0.06 Mil) to Dec. 2025 (kr0.06 Mil).

Monsenso AS's annual Other Stockholders Equity stayed the same from Dec. 2023 (kr0.06 Mil) to Dec. 2024 (kr0.06 Mil) and stayed the same from Dec. 2024 (kr0.06 Mil) to Dec. 2025 (kr0.06 Mil).

Monsenso AS Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Monsenso AS's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Monsenso AS Other Stockholders Equity Chart

Monsenso AS Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only 0.06 0.06 0.06 0.06 0.06

Monsenso AS Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 0.06 0.06 0.06 0.06
OCSE:MONSO
29GF Score
Monsenso AS OCSE:MONSO
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Monsenso AS Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of kr0.06 Mil mean?
Monsenso AS (OCSE:MONSO) has a Other Stockholders Equity of kr0.06 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Monsenso AS and its competitors.
Is Monsenso AS's Other Stockholders Equity too high?
Monsenso AS's current Other Stockholders Equity is kr0.06 Mil. Overall, Monsenso AS has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Monsenso AS's Other Stockholders Equity compare to VEEV and BTSG?
Monsenso AS's Other Stockholders Equity of kr0.06 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Healthcare Providers & Services company?
A good Other Stockholders Equity depends on the Healthcare Providers & Services industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Monsenso AS and its competitors. Monsenso AS's current Other Stockholders Equity is kr0.06 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Monsenso AS stock overvalued right now?
Based on GuruFocus' analysis, Monsenso AS (OCSE:MONSO) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.15, compared to a current price of kr0.30 — trading 100% above its estimated fair value. The current Other Stockholders Equity is kr0.06 Mil. Monsenso AS's overall GF Score™ is 29/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Monsenso AS (OCSE:MONSO), the current Other Stockholders Equity is kr0.06 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Monsenso AS (OCSE:MONSO) Overvalued in 2026?

Based on GuruFocus' analysis, Monsenso AS stock appears to be overvalued. The current stock price of kr0.30 is trading 100% above its estimated GF Value™ of kr0.15. GuruFocus considers Monsenso AS to be Significantly Overvalued.

Key valuation signals for OCSE:MONSO:

  • Other Stockholders Equity: kr0.06 Mil
  • GF Value™: kr0.15 vs. price of kr0.30 (100% above fair value)
  • GF Score™: 29/100 with 8 warning signs

No single metric tells the full story. See the OCSE:MONSO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Monsenso AS Business Description

Address Rosenorns Alle 31, 2, Frederiksberg, DNK, DK-1970
Monsenso AS is a mobile mental health company. It technology company offering a digital health solution used for decentralized trials, remote patient monitoring, and treatment support. The company's mission is to contribute to improved health for more people at lower costs by supporting treatment digitally and leveraging patient-reported outcomes data, and the solution helps optimise the treatment and gives a detailed overview of an individual's health through the collection of outcome, adherence, and behavioral data.
29GF Score

Get the complete analysis for OCSE:MONSO

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.30
Price
kr0.15
GF Value